Population characteristics
| . | MSKCC cohort . | Sheba cohort . |
|---|---|---|
| Recipient age, median (IQR), y | 56 (46-64) | 61 (53-65) |
| Age <60 y | 358 (62) | 110 (48) |
| Age ≥60 y | 215 (38) | 120 (52) |
| Recipient sex | ||
| Male | 329 (57) | 144 (63) |
| Female | 244 (43) | 86 (37) |
| Karnofsky performance status | ||
| 90-100 | 365 (64) | 189 (82) |
| <90 | 207 (36) | 28 (12) |
| Missing | 1 (0.2) | 13 (6) |
| HCT-CI | ||
| 0 | 132 (23) | 37 (16) |
| 1 | 98 (17) | 47 (20) |
| 2 | 106 (18) | 38 (17) |
| 3 | 116 (20) | 40 (17) |
| ≥4 | 121 (21) | 68 (30) |
| Recipient CMV serostatus | ||
| Absent | 222 (39) | 42 (19) |
| Present | 351 (61) | 182 (81) |
| Diagnosis | ||
| Acute myeloid leukemia | 217 (38) | 53 (23) |
| Myelodysplastic syndrome | 125 (22) | 57 (25) |
| Multiple myeloma | 115 (20) | 17 (7) |
| Acute lymphoblastic leukemia | 57 (10) | 15 (7) |
| Myeloproliferative neoplasm | 31 (5) | 4 (2) |
| Chronic myeloid leukemia | 17 (3) | 3 (1) |
| Other leukemia | 9 (2) | 0 (0) |
| Lymphoma | 0 (0) | 81 (35) |
| Disease risk* | ||
| Low/intermediate | 387 (68) | 138 (60) |
| High | 140 (24) | 92 (40) |
| Unclassifiable | 46 (8) | 0 (0) |
| Time from Dx to HCT, median (IQR), mo | 7 (5-25) | 12 (4-34) |
| Donor/recipient sex | ||
| Female/male | 114 (20) | 52 (23) |
| Other | 459 (80) | 175 (77) |
| Donor type† | ||
| Matched related | 192 (34) | 100 (43) |
| Matched unrelated | 283 (49) | 98 (43) |
| HLA mismatched | 98 (17) | 32 (14) |
| HCT year, median (IQR) | 2014 (2012-2016) | 2013 (2012-2014) |
| Regimen (%)‡ | ||
| Melphalan based | 436 (76) | NA |
| TBI based | 137 (24) | NA |
| Fludarabine-treosulfan (30 g/m2) | NA | 33 (14) |
| Fludarabine-treosulfan (36-42 g/m2) | NA | 156 (68) |
| Fludarabine-melphalan (100 mg/m2) | NA | 27 (12) |
| Fludarabine-melphalan (140 mg/m2) | NA | 14 (6) |
| . | MSKCC cohort . | Sheba cohort . |
|---|---|---|
| Recipient age, median (IQR), y | 56 (46-64) | 61 (53-65) |
| Age <60 y | 358 (62) | 110 (48) |
| Age ≥60 y | 215 (38) | 120 (52) |
| Recipient sex | ||
| Male | 329 (57) | 144 (63) |
| Female | 244 (43) | 86 (37) |
| Karnofsky performance status | ||
| 90-100 | 365 (64) | 189 (82) |
| <90 | 207 (36) | 28 (12) |
| Missing | 1 (0.2) | 13 (6) |
| HCT-CI | ||
| 0 | 132 (23) | 37 (16) |
| 1 | 98 (17) | 47 (20) |
| 2 | 106 (18) | 38 (17) |
| 3 | 116 (20) | 40 (17) |
| ≥4 | 121 (21) | 68 (30) |
| Recipient CMV serostatus | ||
| Absent | 222 (39) | 42 (19) |
| Present | 351 (61) | 182 (81) |
| Diagnosis | ||
| Acute myeloid leukemia | 217 (38) | 53 (23) |
| Myelodysplastic syndrome | 125 (22) | 57 (25) |
| Multiple myeloma | 115 (20) | 17 (7) |
| Acute lymphoblastic leukemia | 57 (10) | 15 (7) |
| Myeloproliferative neoplasm | 31 (5) | 4 (2) |
| Chronic myeloid leukemia | 17 (3) | 3 (1) |
| Other leukemia | 9 (2) | 0 (0) |
| Lymphoma | 0 (0) | 81 (35) |
| Disease risk* | ||
| Low/intermediate | 387 (68) | 138 (60) |
| High | 140 (24) | 92 (40) |
| Unclassifiable | 46 (8) | 0 (0) |
| Time from Dx to HCT, median (IQR), mo | 7 (5-25) | 12 (4-34) |
| Donor/recipient sex | ||
| Female/male | 114 (20) | 52 (23) |
| Other | 459 (80) | 175 (77) |
| Donor type† | ||
| Matched related | 192 (34) | 100 (43) |
| Matched unrelated | 283 (49) | 98 (43) |
| HLA mismatched | 98 (17) | 32 (14) |
| HCT year, median (IQR) | 2014 (2012-2016) | 2013 (2012-2014) |
| Regimen (%)‡ | ||
| Melphalan based | 436 (76) | NA |
| TBI based | 137 (24) | NA |
| Fludarabine-treosulfan (30 g/m2) | NA | 33 (14) |
| Fludarabine-treosulfan (36-42 g/m2) | NA | 156 (68) |
| Fludarabine-melphalan (100 mg/m2) | NA | 27 (12) |
| Fludarabine-melphalan (140 mg/m2) | NA | 14 (6) |
Unless otherwise noted, data are n (%).
CMV, cytomegalovirus; Dx, diagnosis; HCT, hematopoietic cell transplantation; NA, not applicable (regimens specific to individual centers).
Disease risk was classified using Center for International Bone and Marrow Transplant Research criteria (MSKCC cohort) and European Society for Blood and Bone Transplantation criteria (Sheba cohort).
Matched donor was defined at an 8/8 HLA allele level for the MSKCC cohort and a 10/10 HLA level at the Sheba Medical Center. Corresponding definitions for mismatched donors were 7/8 and 9/10.
Among patients in the Sheba cohort, 173 (77%) and 51 (23%) received methotrexate-based or mycophenolate mofetil–based GvHD prophylaxis, respectively, and 143 (62%) received anti-thymocyte globulin.